Clinical characteristics of the patients
| Characteristic . | MDS1 . | MDS2 . | MDS3 . | MDS4 . | MDS5 . |
|---|---|---|---|---|---|
| FAB type | RAEB-T | RAEB-T* | RARS | RAEB | RA |
| IPSS | High | Int-1 | Int-1 | Int-1 | Low |
| Age, sex | 68, M | 33, F | 72, M | 76, M | 59, M |
| Hb (g/dL) | 7.5 | 9.6 | 10.7 | 13† | 9.5 |
| Cellularity | Hyper | Hyper | Hyper | Hyper | Hypo |
| M:E ratio | 10:1 | 4:1 | 4:1 | 4:1 | 3:1 |
| Cytogenetics | Normal | Normal | Complex | Normal | Normal |
| Characteristic . | MDS1 . | MDS2 . | MDS3 . | MDS4 . | MDS5 . |
|---|---|---|---|---|---|
| FAB type | RAEB-T | RAEB-T* | RARS | RAEB | RA |
| IPSS | High | Int-1 | Int-1 | Int-1 | Low |
| Age, sex | 68, M | 33, F | 72, M | 76, M | 59, M |
| Hb (g/dL) | 7.5 | 9.6 | 10.7 | 13† | 9.5 |
| Cellularity | Hyper | Hyper | Hyper | Hyper | Hypo |
| M:E ratio | 10:1 | 4:1 | 4:1 | 4:1 | 3:1 |
| Cytogenetics | Normal | Normal | Complex | Normal | Normal |
MDS indicates myelodysplastic syndrome; FAB, French-American-British criteria7,26; RAEB-T, refractory anemia with excess blasts in transformation; RARS, refractory anemia with ringed sideroblasts; RAEB, refractory anemia with excess blasts; RA, refractory anemia; IPSS, International Prognostic Scoring System8; Hb, hemoglobin; M:E ratio, ratio of myeloid and erythroid elements within the marrow aspirate.
Patient MDS2 had been previously treated (MOPP × 8 cycles) during a period 4 years before the diagnosis of MDS.
Without transfusion.